CBAY - CymaBay Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.12
-0.06 (-0.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.18
Open10.26
Bid0.00 x 800
Ask0.00 x 2900
Day's Range9.79 - 10.34
52 Week Range7.63 - 15.59
Volume381,360
Avg. Volume502,627
Market Cap597.614M
Beta (3Y Monthly)2.16
PE Ratio (TTM)N/A
EPS (TTM)-0.97
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.33
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Report: Developing Opportunities within Brunswick, Pebblebrook Hotel Trust, Avaya, Braskem S.A, CymaBay Therapeutics, and The Blackstone Group — Future Expectations, Projections Moving into 2018

    NEW YORK, Oct. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire13 days ago

    CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver Meeting®

    CymaBay Therapeutics, Inc. (CBAY), today announced that two late-breaking presentations describing new long-term data from its ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC) will be featured on November 12, 2018 during The Liver Meeting® hosted by the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA (November 9-13, 2018).  Seladelpar is an orally administered, potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in development for PBC and nonalcoholic steatohepatitis (NASH). The first presentation, abstract LB-3, titled “Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta Agonist, in Primary Biliary Cholangitis: 52-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 Study” will be delivered by Professor Chris Bowlus, MD, Division Chief of Gastroenterology and Hepatology, University of California at Davis Health.

  • GlobeNewswire22 days ago

    CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October

    NEWARK, Calif., Sept. 24, 2018-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today ...

  • Oppenheimer’s 7 Top Stock Picks for September
    Kiplinger28 days ago

    Oppenheimer’s 7 Top Stock Picks for September

    Are you looking for a post-summer portfolio boost? Look no further. Investment firm Oppenheimer has released a bullish report highlighting its latest Top Stock Picks for September 2018. "These are the most timely stocks in the opinion of our research analysts" stated the firm. "Each analyst was asked to contribute the one idea they considered to outperform over the next 12 months, based on their view of the company's fundamentals in the context of current market conditions." The report lists 30 top stocks. But here I focus on the seven stocks that truly stand out from the crowd. I used TipRanks' market data to cherry-pick the report's best stocks. These are the the stocks which boast a "strong buy" consensus rating from the Street. This is based on all the ratings each stock has received over the last three months. That way we have the added reassurance of knowing that these stocks score big across the board.Let's take a closer look at these hot shots now: SEE ALSO FROM KIPLINGER: 12 Top Stock Picks to Shield Your Portfolio

  • Oppenheimer’s 7 Top Stock Picks for September
    InvestorPlace2 months ago

    Oppenheimer’s 7 Top Stock Picks for September

    Investment firm Oppenheimer has just released a bullish report highlighting its latest Top Stock Picks for August-September 2018. “These are the most timely stocks in the opinion of our research analysts” stated the firm.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CBAY earnings conference call or presentation 9-Aug-18 8:30pm GMT

    Q2 2018 CymaBay Therapeutics Inc Earnings Call

  • GlobeNewswire2 months ago

    CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September

    NEWARK, Calif., Aug. 14, 2018-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced ...

  • GlobeNewswire2 months ago

    CymaBay Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    Conference call and webcast today at 4:30p.m. ET. NEWARK, Calif., Aug. 09, 2018-- CymaBay Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for liver and other ...

  • GlobeNewswire2 months ago

    CymaBay to Report Second Quarter 2018 Financial Results on Thursday, August 9

    NEWARK, Calif., Aug. 02, 2018-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced ...

  • New Strong Sell Stocks for August 2nd
    Zacks2 months ago

    New Strong Sell Stocks for August 2nd

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • GlobeNewswire2 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Five Prime Therapeutics, Akorn, The Blackstone Group, Avaya, Tractor Supply, and CymaBay Therapeutics — New Research Emphasizes Economic Growth

    NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Five ...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of CBAY earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 CymaBay Therapeutics Inc Earnings Call

  • ACCESSWIRE5 months ago

    Wired News – CymaBay Therapeutics Starts Phase-2b Clinical Trials of Seladelpar for Treatment of Patients with Non-Alcoholic Steatohepatitis

    LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on CymaBay Therapeutics, Inc. (NASDAQ: CBAY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CBAY as the Company's latest news hit the wire. On May 08, 2018, the Company announced the initiation of Phase-2b proof of concept clinical trials of seladelpar for the treatment of patients with non-alcoholic steatohepatitis (NASH). The Company started the Phase-2b study with the screening of patients for the clinical trials.

  • Analysts’ Ratings for Achaogen and Peers in April 2018
    Market Realist6 months ago

    Analysts’ Ratings for Achaogen and Peers in April 2018

    Achaogen (AKAO), a late-stage biopharmaceutical company, develops and commercializes antibacterial treatments for MDR (multidrug-resistant) gram-negative infections. Its lead product candidate, plazomicin, targets serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, which was identified as a “nightmare bacteria” by the Centers for Disease Control and Prevention in 2013. Of the 12 analysts covering Achaogen in April 2018, five have recommended a “strong buy,” six have recommended a “buy,” and one has recommended a “sell.” The mean rating for the stock is 1.8, and its target price is $21.56.

  • How Has CymaBay Therapeutics Performed Financially?
    Market Realist6 months ago

    How Has CymaBay Therapeutics Performed Financially?

    CymaBay Therapeutics’ (CBAY) MBX-2982 is under evaluation as a novel therapeutic agent. The company has yet to disclose its target indication. The drug was synthesized as a GPR119 agonist and is shown to increase glucose-dependent insulin secretion in animal models and in vitro. Non-clinical studies have shown MBX-2982 to have desirable effects on blood glucose levels.

  • Exploring CymaBay’s Other Promising Product Candidates
    Market Realist6 months ago

    Exploring CymaBay’s Other Promising Product Candidates

    CymaBay Therapeutics’ (CBAY) second product candidate, arhalofenate, is being developed for the treatment of gout. The drug has been studied in five phase two clinical trials in patients suffering from gout and has consistently demonstrated reduction of gout flares and serum uric acid (or sUA). Gout flares are recurring and painful episodes of joint inflammation.

  • Key Updates on CymaBay’s Lead Product Candidate
    Market Realist6 months ago

    Key Updates on CymaBay’s Lead Product Candidate

    CymaBay Therapeutics (CBAY) is currently developing seladelpar for treating primary biliary cholangitis (or PBC), which is an autoimmune disease that causes progressive destruction of the bile ducts in the liver. The company also plans to develop seladelpar for treating non-alcoholic steatohepatitis (or NASH). NASH is a serious chronic liver disease caused by excessive fat accumulation in the liver, which results in inflammation and cellular injury that can progress to fibrosis and cirrhosis and potentially liver failure.

  • What Analysts Recommend for CymaBay Therapeutics
    Market Realist6 months ago

    What Analysts Recommend for CymaBay Therapeutics

    CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with liver disease and other chronic diseases. Of the eight analysts covering CymaBay Therapeutics in April 2018, two analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating. Of the total 22 analysts covering Pfizer (PFE) in April 2018, two analysts have given the stock a “strong buy” rating, and nine analysts have given it a “buy” rating.